# Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers

> **NCT03109847** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 13 (actual)

## Conditions studied

- Thyroid

## Interventions

- **DRUG:** Metformin Hydrochloride
- **OTHER:** Radioactive Iodine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03109847
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-05
- **Primary completion:** 2020-12-29
- **Final completion:** 2022-12-07
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109847, "Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03109847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*